iSpeak

iSpeak Blog
Asia Pacific Pharma Outlook The healthcare market in the Asia Pacific (APAC) region is continuing to grow at a steady rate with an estimated 500-billion-dollar industry by 2020. This is due to rising development in smart manufacturing and government...
iSpeak Blog
Featured in this edition of iSpeak Reading Roundup, are the top blog posts from July 2019. See trending ideas for regulatory compliance, biopharmaceutical innovation, and more for what the pharmaceutical industry was reading last month. Integrated...
iSpeak Blog
The 2019 ISPE Asia Pacific Pharmaceutical Manufacturing Conference will be held 30 September to 1 October in Singapore. The conference is modelled on the regional ISPE conferences held in North America and Europe each year and follows a successful pilot...
iSpeak Blog
How CMOs keep conditions controlled and reduce costs with temporary power, climate control, 100% oil-free air
iSpeak Blog
Ayako Nakajima General Manager Nissan Chemical Corporation in Japan Ayako Nakajima, a General Manager with Nissan Chemical Corporation in Japan, joined ISPE in 2002. In 2011, she became the Director of the ISPE Japan Affiliate, and in 2016, was elected...
iSpeak Blog
You are sitting with a group of people around a table in a conference room. On the wall, a monitor displays a spreadsheet showing the inputs and outputs of a complex manufacturing process in a vast matrix. The purpose of the meeting is to assign risk...
iSpeak Blog
Followers of FDA warning letters and Form 483s will have noticed that over the last 12 – 18 months, there have been increasing mention of data integrity issues around manufacturing data, often as a result of outdated equipment and practices, such as: No...
iSpeak Blog
What is coming next in biopharmaceutical manufacturing? That question was addressed in plenary sessions at the 2019 ISPE Biopharmaceutical Manufacturing Conference 18-20 June in Boston on the second and third days of the conference. View more about the...
iSpeak Blog
As our industry continues to evolve with new and innovative technologies, new product launches, the approval of biosimilars and the continued pressures to drive cost down and quality up, the question remains how to design infrastructure, including both...